Progressive Multiple Sclerosis
Conditions
Brief summary
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis. Secondary Objectives: To assess the following in men and women with progressive multiple sclerosis: * The pharmacokinetic (PK) parameters of GZ402668 after ascending single IV doses. * The pharmacodynamics (PD) of GZ402668 after ascending single IV doses. * The PK parameters of GZ402668 after ascending single SC doses. * The PD of GZ402668 after ascending single SC doses.
Detailed description
The total study duration from screening for a patient can be approximately up to 8 weeks. Upon completion of this trial, patients treated with GZ402668 will be required to enroll in a 4 year safety follow-up study for continued safety observation.
Interventions
DRUGGZ402668
Pharmaceutical form:solution Route of administration: intravenous
DRUGplacebo
Pharmaceutical form:solution Route of administration: intravenous
DRUGacyclovir
Pharmaceutical form:tablet Route of administration: oral
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male or female adult with a diagnosis of progressive multiple sclerosis (MS) including primary progressive MS, secondary progressive MS, and progressive relapsing MS. * Aged between 18 and 65 years, inclusive. * Body weight greater than 40.0 kg. * Female patient of child bearing potential must use 2 highly effective contraception methods. * Male patient, whose partners are of childbearing potential (including lactating women), must accept to use, during sexual intercourse, 2 highly effective contraception methods. Male patient, whose partners are pregnant, must use, during sexual intercourse, a condom from the inclusion up to 4 months after investigational medicinal product administration. * Male patient who has agreed not to donate sperm for 4 months after product administration.
Exclusion criteria
* Significant medical diseases or conditions, including poorly controlled hypertension, cardiovascular disease, inflammatory disorders, immunodeficiency, autoimmune disease, renal failure, liver dysfunction, cancer (except treated basal skin cell carcinoma), or active infection. * Frequent headaches and/or migraine, recurrent nausea and/or vomiting. * History or presence of drug or alcohol abuse. * Smoking more than 5 cigarettes or equivalent per day. * If female, pregnancy, lactating, or breast-feeding. * Patients with relapsing-remitting MS. * Lymphocyte counts below the lower limit of normal. * Treatment with natalizumab, methotrexate, azathioprine, or cyclosporine in the past 6 months. * Treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab or any other immunosuppressant or cytotoxic therapy (other than steroids) in the last 12 months, or determined by the treating physician to have residual immune suppression from these treatments. * Treatment with glatiramer acetate or interferon beta in the past 4 weeks. * Treatment with fingolimod within the past 2 months. * Treatment with dimethyl fumarate in past 4 weeks. * Treatment with teriflunomide within the past 12 months unless patient has completed an accelerated clearance with cholestyramine. * Previous treatment with alemtuzumab. * Live, attenuated vaccine within 3 months prior to the randomization visit, such as varicella-zoster, oral polio, and rubella vaccines. * Clinically significant abnormality in thyroid function. * Inability to undergo magnetic resonance imaging with gadolinium administration. * Hypersensitivity or contraindication to acyclovir. * Known bleeding disorder. * Significant autoimmune disease. * Active infection or at high risk for infection. * Latent or active tuberculosis. * Major psychiatric disorder that is not adequately controlled by treatment. * Epileptic seizures that are not adequately controlled by treatment. * Prior history of invasive fungal infections. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment emergent adverse events | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| area under curve (AUC) | 4 weeks |
| Number of participants with lymphocyte depletion | 4 weeks |
| maximum concentration (Cmax) | 4 weeks |
| Number of participants with injection site reactions | 2 weeks |
| Number of participants with corrected QT interval (QTcF) prolongation | 4 weeks |
| Number of participants with anti-drug antibodies | 4 weeks |
Countries
Germany
Outcome results
None listed